Mutual of America Capital Management LLC Sells 7,261 Shares of Halozyme Therapeutics, Inc. $HALO

Mutual of America Capital Management LLC decreased its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 11.8% in the 3rd quarter, Holdings Channel reports. The fund owned 54,018 shares of the biopharmaceutical company’s stock after selling 7,261 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Halozyme Therapeutics were worth $3,962,000 as of its most recent filing with the SEC.

Several other large investors also recently added to or reduced their stakes in the company. Empowered Funds LLC purchased a new stake in Halozyme Therapeutics during the first quarter valued at about $755,000. Acadian Asset Management LLC bought a new stake in shares of Halozyme Therapeutics in the first quarter valued at approximately $195,000. Public Employees Retirement System of Ohio lifted its stake in shares of Halozyme Therapeutics by 6,594.3% during the 2nd quarter. Public Employees Retirement System of Ohio now owns 38,626 shares of the biopharmaceutical company’s stock valued at $2,009,000 after buying an additional 38,049 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Halozyme Therapeutics by 15.5% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,760 shares of the biopharmaceutical company’s stock valued at $248,000 after buying an additional 639 shares in the last quarter. Finally, QRG Capital Management Inc. boosted its holdings in Halozyme Therapeutics by 14.6% in the 2nd quarter. QRG Capital Management Inc. now owns 5,055 shares of the biopharmaceutical company’s stock worth $263,000 after buying an additional 644 shares during the period. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the stock. HC Wainwright reissued a “buy” rating on shares of Halozyme Therapeutics in a report on Thursday. Wall Street Zen cut Halozyme Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Saturday, December 6th. Zacks Research cut Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, October 6th. Morgan Stanley cut their target price on Halozyme Therapeutics from $80.00 to $79.00 and set an “overweight” rating for the company in a research note on Monday, October 20th. Finally, Citigroup reaffirmed a “market outperform” rating on shares of Halozyme Therapeutics in a report on Tuesday, November 4th. Seven investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $78.80.

Halozyme Therapeutics Price Performance

NASDAQ:HALO opened at $73.34 on Friday. Halozyme Therapeutics, Inc. has a 52-week low of $47.50 and a 52-week high of $79.50. The stock has a fifty day moving average of $68.90 and a 200 day moving average of $68.27. The company has a debt-to-equity ratio of 1.59, a quick ratio of 1.37 and a current ratio of 1.59. The firm has a market capitalization of $8.62 billion, a price-to-earnings ratio of 15.44, a P/E/G ratio of 0.32 and a beta of 0.94.

Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Monday, November 3rd. The biopharmaceutical company reported $1.72 earnings per share for the quarter, topping analysts’ consensus estimates of $1.63 by $0.09. The business had revenue of $354.26 million for the quarter, compared to analyst estimates of $339.18 million. Halozyme Therapeutics had a return on equity of 156.95% and a net margin of 47.91%.The company’s quarterly revenue was up 22.1% compared to the same quarter last year. During the same period in the prior year, the company earned $1.27 EPS. On average, research analysts expect that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Insider Activity at Halozyme Therapeutics

In related news, COO Cortney Caudill sold 4,263 shares of the firm’s stock in a transaction that occurred on Saturday, November 1st. The shares were sold at an average price of $65.19, for a total value of $277,904.97. Following the sale, the chief operating officer directly owned 12,737 shares of the company’s stock, valued at $830,325.03. This trade represents a 25.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Helen Torley sold 16,569 shares of the business’s stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $68.92, for a total transaction of $1,141,935.48. Following the completion of the transaction, the chief executive officer directly owned 708,719 shares of the company’s stock, valued at approximately $48,844,913.48. This represents a 2.28% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 45,661 shares of company stock valued at $3,139,257 over the last three months. 2.40% of the stock is owned by corporate insiders.

Key Stories Impacting Halozyme Therapeutics

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Company raised guidance and posted strong preliminary 2025 metrics — Halozyme updated preliminary 2025 revenue to $1.385–$1.40B and raised 2026 revenue guidance to $1.71–$1.81B; it also lifted royalty, adjusted EBITDA and non‑GAAP EPS guidance, signaling stronger top‑line and cash‑flow outlooks. PR Newswire
• Positive Sentiment: Market reacted to the stronger preliminary results and raised outlook — coverage notes a near‑term share uptick after management lifted 2026 guidance and preliminary 2025 results beat expectations. This supports momentum and re‑rates HALO on growth expectations. Zacks
• Positive Sentiment: Acquisition of Surf Bio expands drug‑delivery capabilities — Halozyme bought Surf Bio (deal up to $400M) to add a hyperconcentration technology that complements its ENHANZE platform, potentially expanding addressable markets for biologics delivery and future royalty streams. Contract Pharma
• Positive Sentiment: Analyst support — H.C. Wainwright reiterated a Buy and keeps a $90 price target, citing strategic and financial strength of the ENHANZE platform, which may sustain analyst/retail demand. InsiderMonkey
• Neutral Sentiment: Longer‑term projections published — Management outlined sustained growth into the 2030s/2040s driven by ENHANZE and new technologies; important for long‑term investors but less decisive for near‑term moves. Benzinga
• Neutral Sentiment: Management call and filings available — Q4/2025 sales/trading call transcript and slides provide detail for modeling royalty cadence, margin assumptions and Surf Bio integration plans; useful for updating forecasts. Seeking Alpha
• Negative Sentiment: EPS guidance nuance — 2026 non‑GAAP EPS was set at $7.75–$8.25 versus consensus ~ $7.86; while revenue/royalty guidance was raised, the EPS range overlaps but is not meaningfully above consensus, which could temper upside for EPS‑sensitive investors. PR Newswire

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.